Regenxbio Inc (RGNX) Stock Analysis

Regenxbio Inc (RGNX) is a publicly traded company in the HEALTHCARE sector. It trades at $6.52, carries a market capitalization of $369.12M. This page summarizes the public market data, fundamentals, and frequently asked questions for RGNX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $6.52
• Market Cap: $369.12M
• EPS: $-5.60
• 52-Week High: $16.19
• 52-Week Low: $5.46

Market Sentiment

Regenxbio Inc currently has a Neutral sentiment score of 0.07.

About Regenxbio Inc

Regenxbio Inc. is a clinical-stage biotechnology company focused on advancing gene therapies for a range of genetic disorders. Utilizing its proprietary AAV9 gene delivery platform, the company develops innovative treatments designed to address genetic defects by enabling cells to produce therapeutic proteins or antibodies that target disease. Headquartered in Rockville, Maryland, Regenxbio is committed to transforming the lives of patients with serious conditions through cutting-edge gene th...

GNG Research Analysis

GNG Research scores Regenxbio Inc (RGNX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RGNX.

Frequently Asked Questions

Does RGNX pay dividends?

Regenxbio Inc (RGNX) does not currently pay a regular dividend.

What is RGNX's market cap?

Regenxbio Inc (RGNX) has a market capitalization of $369.12M with a current stock price of $6.52.